Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
76 hedge funds and large institutions have $465M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 11 closing their positions.
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
7% more funds holding
Funds holding: 71 → 76 (+5)
38% less capital invested
Capital invested by funds: $750M → $465M (-$285M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$7.62M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.39M |
| 3 |
O
OrbiMed
New York
|
+$2.15M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$1.17M |
| 5 |
HF
HRT Financial
New York
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$13.7M |
| 2 |
N
Natixis
Paris,
France
|
-$11.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.14M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.68M |
KNTE Hedge Fund Activity: Q1 2022 in Review
76 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2022, worth a combined $465M — down 38% from $750M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KNTE positions and 11 closed out — a net gain of 5 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $7.62M. The largest seller was VR Adviser, exiting entirely with an estimated $13.7M sold.
- 76 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2022, up from 71 in Q4 2021.
- Funds reported $465M of Kinnate Biopharma Inc. Common Stock stock for Q1 2022, down 38% quarter-over-quarter.
- 16 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2022 and 11 closed out, a net change of +5 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2022 was Lynx1 Capital Management, an estimated $7.62M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2022 was VR Adviser, an estimated $13.7M sold.
Based on aggregated 13F filings for Q1 2022.